article thumbnail

Navigating the unique CMC challenges of oral anaerobic live biotherapeutics

European Pharmaceutical Review

Firstly, the pharmacological response to LBPs does not follow traditional pharmacokinetic principles. About the authors Mike Frodsham has been the Chief Technical Officer for SGS Quay Pharma for over 18 years and holds over 23 years of experience in drug product development. 2015; 69(1):381–403 5. 2021; 19:100306 4.

article thumbnail

Market outlook to 2032: future trends across the seven major markets

European Pharmaceutical Review

Comparatively, in 2015, GlobalData’s research expected that sales of therapies for Gaucher disease will reach $1.16 GlobalData anticipated it will launch in the US and 5EU (France, Germany, Italy, Spain, and the UK) markets during the forecast period, Sulayman Patel, MSci, Pharma Analyst at GlobalData noted. “As billion by 2024.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms

pharmaphorum

Across swathes of primary care, pharmacological innovation has stalled; the last new antihypertensive class was introduced in 2007 and new antibiotics have trickled in at a dangerously slow pace. To thrive, pharma must ask increasingly tough questions about the viability of candidates for clinical development.

FDA 82
article thumbnail

Female sexual interest drug reaches tipping point with Phase III plans

Pharmaceutical Technology

After more than a decade in development, Freya Pharma Solutions plans to advance an oral tablet dubbed Lybrido into Phase III trials to treat female sexual interest/arousal disorder (FSIAD). Moreover, despite the buzz generated when Addyi was launched in 2015, only one other drug has since been marketed.